Handelsavisen
prelaunch
Companies Healthcare IAN.CD
IA
IAN.CD Healthcare Facilities & Services

Ian.Cd

$0,01
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-10,7 %
ROE
39,0 %
Net margin
-27,9 %
Debt / equity
-1,88
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

IAN.CD operates in the pharmaceuticals industry, focusing on drug development and commercialization, primarily generating revenue through product sales and licensing agreements.

Business. IAN.CD operates in the pharmaceuticals industry, focusing on drug development and commercialization, primarily generating revenue through product sales and licensing agreements.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
39,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning IAN.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to IAN.CD. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    IAN.CD operates in the pharmaceuticals industry, focusing on drug development and commercialization, primarily generating revenue through product sales and licensing agreements.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    IAN.CD's capital structure is highly leveraged, with total liabilities of $359.03 million and total equity of -$103.04 million, resulting in a debt-to-equity ratio of -1.88. The company's liquidity position is weak, as evidenced by a current ratio of 0.71, indicating that current assets are insufficient to cover current liabilities. Free cash flow is negative at -$44.83 million, and operating cash flow is only $3.15 million, suggesting limited ability to fund operations or reduce debt.

    Profitability metrics are mixed. The company reported a gross profit of $65.70 million, but this was offset by an operating loss of $15.42 million and a net loss of $40.20 million. Return on equity is high at 39.02%, but this is misleading due to the negative equity base. Return on assets is negative at -15.71%, indicating poor asset utilization.

    Revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's financial snapshot does not provide segment-specific revenue data, but the absence of geographic breakdown suggests potential concentration risk.

    Growth trajectory is uncertain. The company reported revenue of $143.99 million in the latest period, but there is no historical data provided to assess year-over-year growth. Analyst estimates for the last actual revenue were $78.38 million, suggesting a significant increase in the most recent period.

    Risk factors include liquidity constraints and a high debt load. The company has a medium liquidity risk and a low dilution risk, but the negative net cash position after subtracting total debt is a key flag. No recent events or filings are disclosed in the provided data to suggest material changes in the company's risk profile.

    Recent events and filings are not disclosed in the provided data, so no specific information is available on recent corporate actions or regulatory developments affecting the company.

    Key takeaways
    • IAN.CD has a highly leveraged capital structure with a negative equity position.
    • The company's profitability is weak, with a net loss of $40.20 million despite a gross profit of $65.70 million.
    • Liquidity is constrained, with a current ratio of 0.71 and negative free cash flow.
    • Revenue growth appears to have accelerated in the latest period, but historical context is limited.
    • The company faces significant liquidity and debt management challenges.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,01
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$103.0M
    Net cash
    -$194.0M
    Current ratio
    0.7
    Debt / equity
    -1.9
    ROA
    -15.7%
    ROE
    39.0%
    Cash conversion
    -8.0%
    CapEx / revenue
    -16.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-10,7 %Bottom quartile
    Net Margin-27,9 %Bottom quartile
    ROE39,0 %Best in class
    Capex / Rev-16,6 %Bottom quartile
    D/E-1,88Best in class
    Cash Conv-0,08Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • IAN.CD Market data — financials · 2026-05-28
    • Ianthus Capital Holdings Inc Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    IAN.CDCanonical
    — · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage